It didn’t take long for Terry Ross, former president and CEO of PACS firm Cemax-Icon, to find a new job. Ross, who left the Fremont, CA-based firm following the close of its acquisition by Eastman Kodak in December (SCAN 12/16/98), has been
It didnt take long for Terry Ross, former president and CEO of PACS firm Cemax-Icon, to find a new job. Ross, who left the Fremont, CA-based firm following the close of its acquisition by Eastman Kodak in December (SCAN 12/16/98), has been named president of ultrafast CT developer Imatron of South San Francisco, CA. He has served as an Imatron board member for 12 years.
Ross is the second Cemax-Icon executive to leave the company in recent months. Former vice president of sales and marketing Oran Muduroglu left the company in 1998 to head up Stentor, a San Francisco startup formed to commercialize dynamic transfer syntax (DTS), a protocol for low-cost enterprise-wide image distribution developed by a University of Pittsburgh Medical Center PACS research team. A DTS demonstration drew much attention in the infoRAD exhibit area at last years RSNA meeting.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.